The Value of Support Groups

Dorothy Leone-Glasser, RN, HHC, CEO Advocates for Responsible Care,

Chair Georgia Bio Patient Advocacy Alliance

When I was diagnosed with systemic lupus erythematosus at 19 years, I discovered a major void in the treatment of chronic illness –support counseling to help patients understand and cope with the challenges of their disease. To bridge this gap in my own practice as a Nurse Specialist, I took a 3-year internship in Chronic Illness Counseling at Columbia University, NYC.  I was determined to fill that void so I created, a national award winning, Coping with Chronic Illness Project. The major component was providing support groups for those with chronic and terminal illness and their caregivers. The groups offered information and practical life-style engineering methods to address the physical and psychological aspects of illness, coping methods, pain and stress management strategies and communication and relationship skills with navigation approaches to our complex healthcare system.

Today we are partnering with GA Bio-Center for Global Health Innovation (CGHI) to focus on the science of patient input for medical research and development with consideration of downstream regulatory and legislative policy decision making.  In doing so, we can explore gaps in knowledge and other barriers that impede progress, and discuss the value of patient input for research that addresses gaps and barriers that could help move the patient and Bio community forward.

To understand the value of support groups on our patient community, Rx in Reach and CGHI launched a digital campaign to collect survey responses from Georgians about chronic illness support groups through Facebook Ads.

The survey generated 157 responses with 49% of all responders saying they belonged to a chronic illness support group. Although, 45% of all responders said they don’t belong to a support group for chronic illness; 63% of all responders said they would like to join a support group.

Other interesting findings from our survey were:

  • 60% believe support groups are misunderstood 
  • 46% said there a stigma associated with support groups that could lead to members feeling embarrassed
  • Responders stated they joined a support group because of
    • feeling isolated
    • needing help managing illness
    • needing someone to listen
    • their physician suggested it

Our findings show there is a strong stigma associated with seeking help from a support group. Support group members believe the public does not understand the need to connect with others who understand their daily challenges of living with chronic illness. Professional facilitated support groups offer a safe, non-judging environment for people to gain valuable information about disease processes, managing illness symptoms and healthcare system barriers while providing worthwhile life-style engineering to better cope with the rollercoaster of emotions and daily living complications. Survey responders, 20%, stated, their support group experience helped them, especially to feel less isolated and 15% of responders stated their group offered them the opportunity to gain new friends who understand their illness journey.

Summary

We know there are many with chronic illness, their caregivers, family members and friends who would want the chance to join a support group. This presents an opportunity for us to extend our outreach to those who are facing illness feeling alone and misunderstood so we can ensure their voices are heard with aid and encouragement offered to help them live their best life despite being ill. The work of this Patient Advocacy Alliance will continue to bring together our Bio community, patient support group members, advocate and medical organizations to improve health equity throughout our healthcare delivery system and clinical trials, while sharing strategy and actions that address important health policy issues.

Panelists

Kelly Barta headshot

Kelly Barta

Coalition of Skin Diseases, President

After experiencing a prolonged and severe health crisis due to long-term use of topical steroids for eczema, Kelly became a passionate voice for those who were suffering. She was determined to bring change to the way eczema was understood and treated. Her advocacy efforts have led her to serve on several national dermatology nonprofits, bringing awareness to the great needs of this community and supporting those living with eczema and going through topical steroid withdrawal syndrome.

Kelly currently serves as President and CEO of the Coalition of Skin Diseases, an umbrella organization of more than 25 national skin-related patient groups, which exists to raise awareness of skin diseases and advocate for the 84+ million Americans living with skin conditions.

She has served as past president of the International Topical Steroid Awareness Network (ITSAN), and continues to support their mission as member of the Board of Directors. Additionally, Kelly sits on the Patient Advocacy Task Force of the American Academy of Dermatology and the Atopic Dermatitis Advisory Panel for Globalskin. She has presented on eczema and TSW to the FDA as well as before patient, academic and political audiences. Kelly is the recent author of her story, To Eczema With Love, https://toeczemawithlove.com/.

Kelly resides in Atlanta, Georgia with her two sons and enjoys taking in the great outdoors, whether it be the mountains, oceans, a walk in the woods or digging in her own garden.

Barbara Fleeman headshot

Barbara Fleeman

WomenHeart Champion; Support Group Facilitator

Barbara grew up in Atlanta and moved back 6 years ago after spending 40 years building a successful career in entertainment consumer marketing/promotion.  She was always very active in her personal and professional life.  In 2013 she was diagnosed with severe pericarditis.  Over the following 18 months. She continued to experience increasingly difficult episodes of shortness of breath, chest pain, fatigue, nausea, dizziness, and chest pressure.  She went to see several doctors and was told that there was nothing wrong with her heart, even though she told them “My heart hurts”.  She continued to become sicker.  After a long course of indecision by medical professionals, she found help and a correct diagnosis of INOCA and Coronary Microvascular Dysfunction at the Barbra Streisand Women’s Heart Center at Cedars Sinai Medical Center in Los Angeles.

In 2015 she was invited to attend the WomenHeart Science and Leadership Symposium at the Mayo Clinic in Rochester, MN.  After an intensive five-day event, she was trained to become a WomenHeart Champion.  Barbara continues to share her experience with women to help educate them to the unique signs & symptoms of women’s heart disease, as well as, provide patient advocate support to women who are living with or at risk of heart disease.

Christopher Reed headshot

J. Christopher Reed

Lupus Foundation of America-Georgia

Support Group Facilitator, Advocacy Chair

Christopher was diagnosed with lupus in 1990 at the age of 16. Lupus attacked his heart, lungs, kidneys, digestive system, veins, and nervous system. Christopher’s lupus journey began with chronic headaches and frequent muscle spasms then progressed to frequent fevers, arthritis, and tremendous weight loss. He was barely able wrap his hands around the steering wheels during driver’s ed class and walking up the stairwell to his bedroom felt like he was having a heart attack. In 2004, he developed stage 3 kidney disease.  With his first job out of law school, Christopher was juggling kidney disease and horrible chemotherapy treatments. In 2018, he almost lost his life due to septic shock.

Overtime, Christopher continued to suffer from severe organ involvement. He was constantly worried about a lack of insurance and the cost of his life-saving medication.

Despite these serious lupus attacks, and moving back to his parent’s home, Christopher earned a bachelor’s degree with honors from the Georgia State University and a law degree from Tulane University. He attributes his success to God, the support of family and the support received at an early age from the Lupus Foundation of America, Georgia Chapter (LFAGA).

In speaking with Christopher, one can tell he is an avid advocate passionate about tackling healthcare policy and increasing lupus research. He previously chaired the Georgia Council on Lupus Education and Awareness (Council), a sponsored entity created by the state legislature to improve the lives of Georgians living with lupus.  He has worked to establish the Georgia Lupus Collaborative, an advisory group and think tank charged with improving the lives of people with lupus in Georgia.

Christopher currently serves as a Support Group Facilitator, Advocacy Chair, and Project Manager for the Lupus Foundation of America-Georgia Chapter. His support group is specifically designed for men. As Advocacy Chair, he gives presentations on patient advocacy and public health policy as well as being a writer on Lupus. Each year, over a one hundred lupus advocates engage in Lupus Day at the Georgia State Capitol. He remains involved in Health Research and serves to increase African American participation in clinical trials through a series of education sessions, open discussion, and dialogues with African American physicians and African American researchers.

Christopher has been honored to be a recipient of several awards including the Mary Cann Achievement Award from the Lupus Foundation of America, Georgia Chapter.

The post The Value of Support Groups appeared first on Georgia Bio.

June 18, 2026
June 18, 2026 - Athens Bioscience, Inc., a US manufacturer of native human and animal proteins, today announced a change in leadership. Benjamin Newland, the company’s Executive Chairman, has become Chairman and Chief Executive Officer, effective today. John Mitchell, who has led the company as CEO for five years, will continue as special advisor. Karson Durie rejoins Athens as Chief Operating Officer, effective June 8, 2026. Dee Athwal, a biotechnology executive and antibody engineer, will join the board of directors on July 1, 2026. Newland becomes chief executive four decades after his father, Dr. Hillary Newland, co-founded the company that became Athens Bioscience in 1986 at the University of Georgia. Newland has served as Chairman and majority shareholder since March 2024 and is relocating from Spain to Athens, Georgia, to take the role. “For forty years Athens has made native proteins in-house, lot after lot — proteins that researchers and diagnostics labs build their own work on top of,” said Benjamin Newland, Chairman and CEO of Athens Bioscience. “What we want to do now is deepen relationships with our core customers and broaden our distribution.We also intend to develop our custom and contract manufacturing line of business. John was instrumental in building internal systems and processes and now we are ready to scale.” Mitchell led Athens for five years. As special advisor, he will support the transition and continue to advise on customer and commercial matters. “Athens made great proteins long before I showed up. What it needed was a tighter operation behind them – steadier planning, cleaner production, shipments you can count on,” said John Mitchell. “That’s built now. The next thing is getting Athens in front of more of the world and I look forward to supporting Benjamin as he moves forward with that.” Durie returns to Athens as Chief Operating Officer, having most recently served as Director of Product Development at Danimer Scientific. She previously served as Lab Director at Athens. She holds a PhD in polymer chemistry and an MBA in finance from the University of Georgia and is a Project Management Professional (PMP) and a registered patent agent. “I know this facility and the people in it,” said Karson Durie, Chief Operating Officer of Athens Bioscience. “Returning as COO is a chance to scale what already works — consistent lots, tight quality control, reliable supply — as demand grows across diagnostics and cell culture.” Athwal will join the board on July 1. He trained as a biophysicist and established the antibody engineering group at Celltech, where he is named as an inventor on foundational antibody-engineering patents. He has founded or co-founded five biotechnology companies and held C-level roles across the UK, US, Europe, Asia, and Latin America, including building Complement Therapeutics as CEO and leading the biologics strategy at Kelix Bio through its acquisition by Mubadala. His work in antibodies, immune proteins, and complement biology maps directly to Athens’s largest product lines. About Athens Bioscience  Athens Bioscience, Inc. (formerly Athens Research & Technology) manufactures native human and animal proteins for research, cell culture media, and in vitro diagnostics. Founded in 1985 at the University of Georgia, the company purifies more than 170 native proteins in-house at its ISO 9001:2015-certified facility in Athens, Georgia. Athens proteins have been cited in more than 2,500 peer-reviewed publications and reach customers across the US, Europe, Asia, the Middle East, and Africa. Athens does not resell or broker. It manufactures. Media Contact Christie DeMasi Athens Bioscience, Inc. christie@athensbioscience.com +1.706.546.0207
June 17, 2026
As part of the Georgia Life Sciences Summit (August 25–26), applications are now open for the Startup Showcase , sponsored by Johnson & Johnson , highlighting early-stage innovation across MedTech and Therapeutics . The Showcase will feature some of Georgia’s most innovative life science startups, giving emerging companies the opportunity to present groundbreaking technologies, products, and solutions to a distinguished audience of industry leaders, investors, researchers, and partners. Selected startups will present during the August 26 luncheon program and participate in a live investor Q&A session with John Gutierrez (Ascenta Capital), Emma Heckenberg, Ph.D. (Solas BioVentures), Patrick Jordan (NovaQuest Capital Management), and Emily Dinu (Numinous Capital) Members of the Johnson & Johnson external innovation team will also be onsite for the program and select companies will be scheduled for a 1:1 meeting to discuss strategic alignment and potential collaboration opportunities. If you or companies in your network are building in MedTech or Therapeutics, this is a strong opportunity to gain visibility, receive feedback on commercialization and growth strategy, and connect with key stakeholders. All applicants receive a complimentary Summit registration, and one selected company will also be invited to participate in the NewYorkBIO / New York Stock Exchange Life Sciences Showcase on December 10. If this is relevant to your work, it would be a strong opportunity to consider applying. If not, it may be worth sharing with companies in your network who are building in this space.
June 15, 2026
Workforce & Education Impact: Building Georgia's Future  Life Sciences Workforce - One Teacher at a Time June 16, 2026 - As Georgia Life Sciences concludes the 2025-2026 cycle of the Biotech Teacher Training Initiative (BTTI), the results reinforce the critical role educators play in building the state's future life sciences workforce. Since July of 2025, BTTI engaged 98 educators representing 40 schools across 23 school systems, reaching an estimated 5,375 students through hands-on biotechnology instruction, career-connected learning, and industry-relevant classroom experiences. The Georgia Life Sciences Equipment Depot further expanded the program's impact by supporting 238 teachers with access to laboratory equipment and materials that make authentic life sciences learning possible. Georgia Life Sciences is also pleased to report that funding for BTTI was maintained in the Georgia House version of the FY 2027 budget approved earlier this year. The upcoming 2026-2027 program cycle will mark an important evolution for BTTI. Building on feedback from industry partners and workforce trends across the life sciences sector, Georgia Life Sciences will expand the program's scope to better reflect the skills and competencies employers increasingly need. In addition to foundational biotechnology concepts, future programming will be organized around key industry domains, including Quality Assurance and Quality Control (QA/QC), Research & Development (R&D), MedTech, Artificial Intelligence, Automation, and Advanced Manufacturing. This expanded approach will provide educators with greater insight into the breadth of career opportunities available across Georgia's life sciences ecosystem while helping students develop awareness of the technologies and disciplines shaping the industry's future. The impact extends far beyond individual workshops, creating lasting connections between Georgia classrooms and the state's growing life sciences ecosystem while helping build the talent pipeline that will power Georgia's future innovation economy. "Before BTTI, I was hesitant to do biotech labs because they seemed too complex and expensive," shared Josephine Jeganathan of Stockbridge High School. "The program showed me how simplified it can be and provided the equipment and materials needed to successfully implement the Central Dogma Lab with all my classes." Teachers are also seeing increased student engagement through hands-on learning experiences. Tonie Curry of North Clayton High School used a chromatography lab to connect environmental science concepts to water pollution and sustainability. "Students were highly interested in seeing how substances separated and made strong connections to water pollution and environmental sustainability," Curry noted. "The hands-on nature of the lab encouraged curiosity and deeper understanding." For many educators, one of the most valuable aspects of the program is the connection between classroom learning and real-world careers. As Marshai Waiters of Marietta Middle School reflected: "Exposure is key. There are so many avenues to work in STEM, and they are all accessible with opportunity and knowledge. The insights gained from industry speakers will inform my teaching and create new opportunities for student exposure." When teachers are trained, equipped, and connected to industry, students gain more than a science lesson—they gain a window into Georgia's life sciences future.
MORE POSTS